Press release

Home/Press release

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

20210310 Transgene TG4001 randomized Phase II EN

By |2021-03-10T16:23:07+01:00March 10th, 2021|Press release, TG4001, TG4001|Comments Off on Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
Go to Top